Off-Label Communication Has Risks Beyond Prosecution, Sheehan Says
Executive Summary
Pharmaceutical companies should beware of pitfalls of communicating about off-label uses even when such activities can be defended as free speech, Philadelphia Associate U.S. Attorney Jim Sheehan suggested